- No file added yet -

Supplementary Tables 1 through 6 from Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations

dataset

posted on 2023-03-30, 22:45 authored by Francesca Ricci, Francesca Bizzaro, Marta Cesca, Federica Guffanti, Monica Ganzinelli, Alessandra Decio, Carmen Ghilardi, Patrizia Perego, Robert Fruscio, Alessandro Buda, Rodolfo Milani, Paola Ostano, Giovanna Chiorino, Maria Rosa Bani, Giovanna Damia, Raffaella Giavazzi

Supplementary Table 1.Primers used for PCR amplification and sequencing Table 2. Clinico-pathological characteristics of the patients from which tumor specimens were trasplanted in nude mice. Table 3.Correlation analysis between engrafted and no-engrafted tumors. Table 4. Mutational spectrum of different genes in EOC-xenograft and corresponding patient tumor Table 5. Genes copy number in EOC-xenoograft and corresponding patient tumors Table 6. Functional analysis on genes differentially expressed in EOC-xenografts and corresponding patient tumors

History

ARTICLE ABSTRACT

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. On the basis of its histopathology and molecular-genomic changes, ovarian cancer has been divided into subtypes, each with distinct biology and outcome. The aim of this study was to develop a panel of patient-derived EOC xenografts that recapitulate the molecular and biologic heterogeneity of human ovarian cancer. Thirty-four EOC xenografts were successfully established, either subcutaneously or intraperitoneally, in nude mice. The xenografts were histologically similar to the corresponding patient tumor and comprised all the major ovarian cancer subtypes. After orthotopic transplantation in the bursa of the mouse ovary, they disseminate into the organs of the peritoneal cavity and produce ascites, typical of ovarian cancer. Gene expression analysis and mutation status indicated a high degree of similarity with the original patient and discriminate different subsets of xenografts. They were very responsive, responsive, and resistant to cisplatin, resembling the clinical situation in ovarian cancer. This panel of patient-derived EOC xenografts that recapitulate the recently type I and type II classification serves to study the biology of ovarian cancer, identify tumor-specific molecular markers, and develop novel treatment modalities. Cancer Res; 74(23); 6980–90. ©2014 AACR.